Molecular imaging and magnetic resonance imaging in early diagnosis of alzheimer's disease. A literature review

Neuroradiology Journal

Volumn 21, Issue 6, 2008, Pages 755-771

  Schillaci, O ^a   Travascio, L ^a   Bruni, Chiara ^a   Bazzocchi, G ^a   Testa, A ^a   Garaci, F G ^a   Melis, M ^a   Floris, R ^a   Simonetti, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Alzheimer's disease; Magnetic resonance; Molecular imaging; Nuclear medicine; PET; SPECT

Indexed keywords

2BETA CARBOMETHOXY 3BETA(4 IODOPHENYL) N (3 FLUOROPROPYL)NORTROPANE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CYSTEINE ETHYL ESTER TC 99M; DONEPEZIL; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INOSITOL; METHYL 4 PIPERIDYL ACETATE C 11; METHYLPIPERIDIN 4 YL PROPIONATE C 11; N ACETYLASPARTIC ACID; PHOSPHORUS; PHYSOSTIGMINE C 11; PROTON; QUINUCLIDINYL BENZILATE I 123; RADIOISOTOPE; SODIUM; TRACER; UNCLASSIFIED DRUG; XANOMELINE;

ALZHEIMER DISEASE; BRAIN ATROPHY; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; EARLY DIAGNOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; MOLECULAR IMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; PHOTON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 59349089823     PISSN: 11209976     EISSN: None     Source Type: Journal    
DOI: 10.1177/197140090802100603     Document Type: Review

References (62)

1. Ryu EK, Chen X: Development of Alzheimer's disease imaging agents for clinical studies. Front Biosci 13: 777-89, 2008.
2. Petrella JR, Coleman RE, Doraiswamy PM: Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 226: 315-36, 2003.
3. Jagust W: Molecular neuroimaging in Alzheimer's disease. NeuroRx 2: 206-12, 2004.
4. Duara R, Barker W, Luis CA: Frontotemporal dementia and Alzheimer's disease: differential diagnosis. Dement Geriatr Cogn Disord 10: 37-42, 1999.
5. Price JL, Davis PB, Morris JC et Al: The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 12: 295-312, 1991.
6. Ramani A, Jensen JH, Helpern JA: Quantitative MR imaging in Alzheimer disease. Radiology 241: 26-44, 2006.
7. Jack CR Jr, Brentley MD, Twomey CK et Al: MR imaging based volume measurements of the hippocampal formation and anterior temporal lobe:validation study. Radiology 176: 205-209, 1990.
8. Jack CR Jr, Petersen RC, Xu Y et Al: Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55: 484-489, 2000.
9. Fox NC, Crum WR, Scahill RI et Al: Imaging of onset and progression of Alzheimer's disease with voxel compression mapping of serial magnetic resonance images. Lancet 358: 201-205, 2001.
10. Karas GB, Burton EJ, Rombouts SARB et Al: A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage 18: 897-907, 2003.
11. Braak E, Griffing K, Arai K et Al: 1999, Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 249: 14-22, 2004.
12. Ramani A, Jensen JH, Helpern JA: Quantitative MR imaging in Alzheimer disease. Radiology 241: 26-44, 2006.
13. Basser PJ, Mattiello J, Turner R et Al: Diffusion tensor echo-planar imaging of human brain. In: Proceedings of the SMRM 1993: 584.
14. Kantarci K, Jack CR, Xu YC et Al: Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 219: 101-107, 2001.
15. Stahl R, Dietrich O, Teipel SJ et Al: White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology 243: 483-92, 2007.
16. Fellgiebel A, Wille P, Muller MJ et Al: Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord 18: 101-108, 2004.
17. Castillo M, Kwock L, Mukherji SK: Clinical applications of proton MR spectroscopy. Am J Neuroradiol 17: 1-15, 1996.
18. Chen JG, Charles HC, Barboriak DP et Al: Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta Neurol Scand Suppl 176: 20-26, 2000.
19. Bruhn H, Frahm J, Gyngell ML et Al: Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 172: 541-548, 1989.
20. Jessen F, Block W, Traber F et Al: Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55: 684-688, 2000.
21. Haussinger D, Laubenberg J, vom Dahl S et Al: Proton magnetic resonance spectroscopy studies of human brain myoinositol in hypoosmolarity and hepatic encephalopathy. Gastroenterology 107: 1475-1480, 1994.
22. Shonk TK, Moats RA, Gifford P et Al: Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195: 65-72, 1995.
23. Mullins PG, Rowland L, Bustillo J et Al: Reproducibility of 1H-MRS measurements in schizophrenic patients. Mag Reson Med 50, 704-707, 2003.
24. Satlin A, Bodick N, Offen WW et Al: Brain proton magnetic resonance spectroscopy (H.MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 cholinergic agonist. Am J Psychiatry 154: 1459-1461, 1997.
25. Buckner RL, Kelley WM, Petersen SE: Frontal cortex contributes to human memory formation. Nat Neurosci 2: 311-314, 1999.
26. Bookheimer SY, Strojwas MH, Cohen MS et Al: Patterns of brain activation in people at risk for Alzheimer disease. N Engl J Med 343: 450-456, 2000.
27. Petrella JR, Krishnan S, Slavin MJ et Al: Mild cognitive impairment: evaluation with 4T functional MR imaging. Radiology 240: 177-186, 2006.
28. Harris GJ, Lewis RF, Satlin A et Al: Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. Am J Neuroradiol 19: 1727-1732, 1998.
29. Bozzao A, Floris R, Baviera ME et Al: Diffusion and perfusion MR imaging in cases of Alzheimer disease: correlations with cortical atrophy and lesion load. Am J Neuroradiol 22: 1030-1036, 2001.
30. Silva AC, Williams DS, Koretsky AP: Evidence for the exchange of arterial spin-labeled water with tissue water in rat brain from diffusion sensitized measurements of perfusion. Magn Reson Med 38: 232-7, 1997.
31. Kim ST: MR Perfusion Imaging of Alzheimer's Disease with Arterial Spin Labeling (ASL). Dementia and Neurocognitive Disorders 5: 1-4, 2006.
32. Johnson NA, Jahng JH, Weiner MW et Al: Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234: 851-859, 2005.
33. Tang BN, Minoshima S, George J et Al: Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow. Eur J Nucl Med Mol Imaging 31: 1487-94, 2004.
34. Okamura N, Shinkawa M, Arai H et Al: Prediction of progression in patients with mild cognitive impairment using IMP-SPECT. Nippon Ronen Igakkai Zasshi 37: 974-978, 2000.
35. Huang C, Wahlund LO, Svensson et Al: Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol 12: 2-9, 2000.
36. Jagust W, Thisted R, Devous MD Sr et Al: SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical pathologic study. Neurology 56: 950-956, 2001.
37. Ishii K, Yamaji S, Kitagaki H et Al: Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 53: 413-416, 1999.
38. Walker Z, Costa DC, Walker RW et Al: Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73: 134-40, 2002.
39. Bonte FJ, Harris TS, Roney CA et Al: Differential diagnosis between Alzheimer's and frontotemporal disease by the posterior cingulate sign. J Nucl Med 45: 771-774, 2004.
40. Brown D, Chisholm JA, Owens J et Al: Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease. Eur J Nucl Med Mol Imaging 30: 296-300, 2003.
41. Mega MS, Dinov ID, Lee L et Al: Oribital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 12: 209-218, 2000.
42. Reiman EM, Chen K, Alexander GE et Al: Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 101: 284-9, 2004.
43. Wolfe MS: The secretases of Alzheimer's disease. Curr Top Dev Biol 54: 233-261, 2003.
44. Cross A: Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann N Y Acad Sci 600: 405-415, 1990.
45. Cohen RM: The application of positron-emitting molecular imaging tracers in Alzheimer's disease. Mol Imaging Biol 4: 204-16, 2007.
46. Tanaka N et Al: Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer's disease. J Cereb Blood Flow Metab 21: 295-306, 2001.
47. Bohnen NI et Al: Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60: 1745-1748, 2003.
48. Rinne JO et Al: Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry 74: 113-115, 2003.
49. Herholz K, Weisenbach S, Kalbe E et Al: Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport 16: 1431-1434, 2005.
50. Nordberg A, Lundqvist H, Hartvig P et Al: Kinetic analysis of regional (S)-11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 9: 21-7, 1995.
51. Mattson MP: Pathways towards and away from Alzheimer's disease. Nature 430: 631-9, 2004.
52. Klunk WE, Engler H, Nordberg A et Al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319, 2004.
53. Kemppainen NM, Aalto S, Wilson IA et Al: Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 67: 1575-80, 2006.
54. Edison P, Archer HA, Hinz R et Al: Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68: 501-8, 2007.
55. Fagan AM, Mintun MA, Mach RH et Al: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59: 512-9, 2006.
56. Pike KE, Savage G, Villemagne VL et Al: β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130: 2837-2844, 2007.
57. Small GW, Kepe V, Ercoli LM et Al: PET of Brain Amyloid and Tau in Mild Cognitive Impairment. New Engl J Med 355: 2652-2663, 2006.
58. Verhoeff NP et Al: In-vivo imaging of Alzheimer disease betaamyloic with [11C]SB-13 PET. Am J Geriatr Psychiatry 12: 584-595, 2004.
59. Mathis CA, Lopresti BJ, Klunk WE: Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 34: 809-22, 2007.
60. Kadir A, Andreasen N, Almkvist O et Al: Effect of phenserine treatment on brain functional activity and amyloid in AD. Ann Neurol 63: 621-631, 2008.
61. McMahon PM, Araki SS, Sandberg EA et Al: Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 228: 515-22, 2003.
62. Ishii K, Minoshima S: PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32:1463-5, 2005.